Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.
The discussion will address the unmet medical need in Traumatic Brain Injury (TBI), commonly known as concussion, explore common causes, and examine its association with other long-term neurological disorders. Additionally, the company will present its lead drug candidate, ONP-002, an innovative neurosteroid designed to treat mild TBI and discuss its outcomes from preclinical and Phase I trials, as well as details of an upcoming Phase II clinical trial to be conducted in acute and emergency departments. Details for the webinar are as follows:
Webinar Topic: Neurotrauma Medicine
When: Monday, May 20, 2024
Time: 12:00 PM Eastern Time
Register: Webinar Link
Speakers:
- James P. Kelly, MA, MD, FAAN, FANA, Emeritus Professor of Neurology and PM&R, University of Colorado School of Medicine
- Frank Peacock, IV, MD, FACEP, FACC, FESC, Vice Chair for Emergency Medicine Research, Baylor College of Medicine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.